The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice (Q38905825)

7 September 2017

The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice (English)

1 reference

7 September 2017

0 references

8

Mayling Alvarez

1 reference

7 September 2017

Lidice Bernardo

1

1 reference

7 September 2017

Alequis Pavón

2

1 reference

7 September 2017

Lisset Hermida

3

1 reference

7 September 2017

Lázaro Gil

4

1 reference

7 September 2017

Iris Valdés

5

1 reference

7 September 2017

Sheila Cabezas

6

1 reference

7 September 2017

Ramón Linares

7

1 reference

7 September 2017

Ricardo Silva

9

1 reference

7 September 2017

Gerardo Guillén

10

1 reference

7 September 2017

Eszter Nagy

11

1 reference

7 September 2017

Petra Schlick

12

1 reference

7 September 2017

María G Guzmán

13

1 reference

7 September 2017

language of work or name

English

0 references

publication date

27 March 2011

1 reference

7 September 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

7 September 2017

29

1 reference

7 September 2017

25

1 reference

7 September 2017

4256-4263

1 reference

Towards a dengue vaccine: progress to date and remaining challenges

7 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Modulating vaccine responses with dendritic cells and Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Separation and quantification of a novel two-component vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Cysteine mediated multimerization of a recombinant dengue E fragment fused to the P64k protein following immobilized metal ion affinity chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Vaccine adjuvants: current state and future trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Characterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and Two Dengue Virus Type 2 Protein Vaccines in Rhesus Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Protective anti-mycobacterial T cell responses through exquisitein vivo activation of vaccine-targeted dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

A Protective Role for Dengue Virus-Specific CD8+ T Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Antibody-dependent cellular cytotoxicity mediated by plasma obtained before secondary dengue virus infections: potential involvement in early control of viral replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Infection-Enhancing and -Neutralizing Activities of Mouse Monoclonal Antibodies against Dengue Type 2 and 4 Viruses Are Controlled by Complement Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.040

10.1016/J.VACCINE.2011.03.040

7 January 2021

Identifiers

DOI

1 reference

7 September 2017

1 reference